Cargando…

Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema

Subcutaneous C1‐inhibitor (HAEGARDA, CSL Behring), is a US Food and Drug Administration (FDA)‐approved, highly concentrated formulation of a plasma‐derived C1‐esterase inhibitor (C1‐INH), which, in the phase III Clinical Studies for Optimal Management in Preventing Angioedema with Low‐Volume Subcuta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Tortorici, Michael A., Pawaskar, Dipti, Pragst, Ingo, Machnig, Thomas, Hutmacher, Matthew, Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Longhurst, Hilary, Sidhu, Jagdev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869560/ https://www.ncbi.nlm.nih.gov/pubmed/29316335 http://dx.doi.org/10.1002/psp4.12271

Ejemplares similares

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate
por: Zuraw, B. L., et al.
Publicado: (2015)

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
por: Levy, Donald, et al.
Publicado: (2020)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)

Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
por: Bernstein, Jonathan A., et al.
Publicado: (2019)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
por: Levy, Donald S., et al.
Publicado: (2020)

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies
por: Bonner, Nicola, et al.
Publicado: (2015)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk
por: Reshef, A, et al.
Publicado: (2015)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
por: Longhurst, Hilary
Publicado: (2018)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
por: Feussner, Annette, et al.
Publicado: (2014)

Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema
por: Steiner, Urs C., et al.
Publicado: (2018)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Management of acute attacks of hereditary angioedema: role of ecallantide
por: Duffey, Hannah, et al.
Publicado: (2015)

Hereditary Angioedema Attack in Utero and Treatment of the Mother and Fetus
por: Grivcheva-Panovska, Vesna, et al.
Publicado: (2020)

Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema
por: Craig, Timothy, et al.
Publicado: (2017)

Ongoing Contact Activation in Patients with Hereditary Angioedema
por: Konings, Joke, et al.
Publicado: (2013)

C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option
por: Longhurst, H J, et al.
Publicado: (2007)

455 Characterization of the Factors Triggering an Edematous Attack in Hereditary Angioedema
por: Zotter, Zsuzsanna, et al.
Publicado: (2012)

The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack
por: Park, Erin G, et al.
Publicado: (2022)

Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks
por: Bernstein, Jonathan A., et al.
Publicado: (2020)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report
por: Bork, Konrad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s22jetbk3uujrsc2qmcqkaj143